Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it will present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference on Wednesday, August 5, 2009 at the Millennium Broadway Hotel in New York City.
Antares Pharma’s President and Chief Executive Officer, Paul K. Wotton, Ph.D. will present Wednesday, August 5th at 4:30 p.m. ET (Eastern Time).
Investors may access a live audio web cast of Antares's presentation at the following link: http://www.bmocm.com/conferences/2009healthcare/webcast/. A web cast replay of the presentation can also be accessed via Antares’s website at www.antarespharma.com, under the Investors section.
About Antares Pharma
Antares Pharma is a product development company committed to improving pharmaceuticals through its patented drug delivery systems. Antares has multiple development partnerships with leading pharmaceutical companies. The Company’s products are designed to improve safety and efficacy profiles by minimizing dosing and reducing side effects while enabling improved patient compliance. Antares has three validated drug delivery systems: the ATDTM Advanced Transdermal Gel Delivery system; subcutaneous injection technology platforms, including VibexTM disposable pressure-assisted auto injectors, ValeoTM/Vision® reusable needle-free injectors, and disposable multi-use pen injectors; and Easy TecTM oral disintegrating tablets (ODT). Two of the systems have generated FDA-approved products. Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements regarding the Company's intentions to submit a Plan with the NYSE Amex to regain compliance with the NYSE Amex listing requirements. These statements are subject to risks and uncertainties including the Company's ability to timely file the Plan, whether the NYSE Amex approves the Plan and the Company's ability to make progress on the actions set forth in the Plan. Such forward-looking statements include statements related to the Company’s future financial performance, and other statements which are other than statements of historical facts. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "intends," "plans," anticipates," "believes," "estimates," "predicts," "projects," "potential," "continue," and other similar terminology or the negative of these terms, but their absence does not mean that a particular statement is not forward-looking. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated by the forward-looking statements. Additional information concerning factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and in the Company's other periodic reports and filings with the Securities and Exchange Commission, particularly those risk factors related to the Company's clinical trial process and ability to gain FDA approval for its product candidates and the Company's ability to raise additional capital. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.
Robert F. Apple, +1 609-359-3020
Lisa Wilson, + 1 917-543-9932